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Available online xxxxEpigenetic events have been linked with disease expression in individuals genetically predisposed to the devel-
opment of systemic lupus erythematosus (SLE), a severe systemic autoimmune/inﬂammatory disease. Altered
DNAmethylation and hydroxymethylation aswell as histonemodiﬁcationsmediate changes in chromatin acces-
sibility and gene expression in immune cells fromSLE patients. Defective epigenetic control contributes to uncon-
trolled expression of inﬂammatory mediators, including cytokines and co-receptors, resulting in systemic
inﬂammation and tissue damage. While the pathophysiological involvement of epigenetic changes in SLE has
been accepted for some time, we only recently started to investigate and understand molecular events contrib-
uting to epigenetic dysregulation. Here, epigenetic alterations will be discussedwith a focus on underlingmolec-
ular events that may be target of preventative measures or future treatment strategies.
© 2018 Elsevier Inc. All rights reserved.Keywords:
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Remodeling1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune/in-
ﬂammatory disease that is characterized by systemic inﬂammation,
the presence of autoantibodies and autoreactive lymphocyte popula-
tions. Despite considerable efforts and recent advances in understand-
ing the molecular pathophysiology of SLE, it remains largely unknown
[1].
Mutations in single genes may result in severe immune dysregula-
tion and the clinical picture of SLE or SLE-like disease. However, only
1–4% of all SLE patients develop so-called monogenic disease [1,2].
While sharing key clinical characteristics with “classical” SLE, mono-
genic disorders usuallymanifests early in life, show almost equal gender
distribution. A considerable proportion of patients with “monogenic
SLE” do not exhibit autoantibodies, or may develop them later as a sec-
ondary phenomenon. Indeed, most currently known monogenic forms
of SLE or SLE-like disease fulﬁll criteria of autoinﬂammatory diseases,
as opposed to autoimmune disease [2,3]. Monogenic disease and
early-onset SLE are discussed elsewhere and are beyond the scope of
this manuscript [4,5].
In most individuals with SLE, genetic predispositions increase the
risk for disease, but additional factors are required for diseaseImmunol. (2018), https://doiexpression. “Pathophysiological co-factors” include female gender and
associated hormonal factors (adolescent girls and women are 9–10
times more frequently affected than boys/men), environmental expo-
sure (including infections, medication, toxins, chemicals, etc.), and epi-
genetic alterations that may be caused or inﬂuenced by the
aforementioned factors. Usually, non-genetic factors accumulate over
time, which may be the reason why ‘classical’ SLE usually manifests
later during adolescence or early adulthood [1,2,5–8].
Over the recent 15–20 years, the role of epigenetic alterations in the
molecular pathophysiology of SLE became increasingly clear [1,2,5–9].
Heritable, but generally reversible molecular events are summarized
as epigenetic mechanisms. Under physiological conditions, epigenetic
mechanisms control the accessibility of genomic DNA to components
of the transcriptional complex, including transcription factors and RNA
polymerases, regulating gene transcription in a cell-, tissue-, and
signal-speciﬁc manner. Thus, epigenetic mechanisms are centrally in-
volved in cell and tissue diversity in the human body (with the excep-
tion of gametes, all cells in the body share the same genotype)
[10–12]. A number of molecular events contribute to shaping the epige-
nome, including DNA methylation, DNA hydroxymethylation, and his-
tone modiﬁcations. Disturbances to the epigenome are involved in
altered gene regulation, the expression of co-receptors, cytokines, and/
or intracellular signals in SLE and other autoimmune disorders [2,12].
In the following, disease-associated epigenetic alterations and underly-
ing molecular events will be discussed..org/10.1016/j.clim.2018.02.002
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2.1. DNA methylation
The addition of a methyl group to the 5′ carbon position of cytosine
within cytosine-phosphate-guanosine (CpG) dinucleotides potently in-
hibits the recruitment of transcriptional regulators to genomic regulatory
elements. DNA methylation is conferred by DNA methyltransferases
(DNMTs). Maintenance DNMT enzymes (DNMT1 and DNMT2) are
mainly responsible for re-methylation of daughter stands during cell divi-
sion, while de novo DNMTs (DNMT3a and DNMT3b) confer DNAmethyl-
ation at previously not methylated regions. However, this may be an
oversimpliﬁcation and some of the functions may be redundant between
the two DNMT classes [2,6,7]. In addition to DNMTs, several proteins and
pathways are involved in controllingDNAmethylationpatterns, including
protein kinases and DNA repair pathways.
The central involvement of DNAmethylation in the pathophysiology
of SLE has been established. Global DNAmethylation is reduced in lym-
phocytes from patients with SLE, and reduced DNA methylation corre-
lates with disease activity [2,7,10]. However, DNA methylation
patterns are complex, region-, cell-, and/or tissue-speciﬁc. Through in-
terplay with other epigenetic events these are involved in molecular
ﬁne tuning [7,8]. The central involvement of DNAmethylation in SLE pa-
thology is particularly underscored by the observation of Javierre et al.
that aberrant DNA methylation patterns distinguish between SLE pa-
tients and healthy siblings in genetically identical disease discordant
monozygotic twins [13]. To date, a considerable number of genes in var-
ious immune cells has been demonstrated to undergo altered DNA
methylation in SLE (Table 1).
2.2. DNA hydroxymethylation
Recently, DNA hydroxymethylation was identiﬁed as epigenetic
mechanism and linked with the pathophysiology of autoimmune/in-
ﬂammatory conditions, including SLE [58,59]. Hydroxymethylated
DNA acts as an intermediate on the way from heavily methylated DNA
to open chromatin through active and passive DNA demethylation
(see below). Indeed, DNA hydroxymethylation is currently considered
an activating epigenetic mark and reﬂects transcriptional activity
of genes [60–62]. Indeed, the observation that depletion of
hydroxymethylation conferring ten eleven translocation (TET) proteins
does not necessarily result in increased DNA methylation, DNA
hydroxymethylation is considered an independent and stable epige-
netic mark that can exert by itself regulatory functions [63]. Generally,
increased mRNA expression in active SLE patients suggests that in-
creased TET activity may result in DNA hydroxymethylation and in-
creased gene expression. Whether altered abundance or activity of
TET proteins, or over-abundance of co-factors play a role in altered
DNA hydroxymethylation in SLE remains elusive. Indeed, while on a
genome-wide level increased, exact hydroxymethylation patterns are
very complex and our understanding of its contribution to altered
gene regulation in SLE is superﬁcial [2,59,64,65] (Table 2) (Fig. 1).
2.3. Histone modiﬁcations
Post-translational modiﬁcations to N terminal amino acid restudies
of histone proteins regulate accessibility of regulatory regions to tran-
scription factors and RNA polymerases by adjusting their three-
dimensional arrangement. In eukaryotic cells, histone proteins aggre-
gate in octamers with two copies of each histone H2A, H2B, H3 and
H4. Histone octamers form complexes with genomic DNA, and 147
base pair spanning stretches of DNA are wrapped around them. These
DNA:histone complexes are referred to as nucleosomes [2,6,8,12]. His-
tone modiﬁcations are manifold and among others include acetylation,
phosphorylation, citrullination, and methylation. Activating or “open-
ing” histone modiﬁcations include H3 lysine 18 acetylation (H3K18ac)Please cite this article as: C.M. Hedrich, Clin. Immunol. (2018), https://doior H3 lysine 4 tri-methylation (H3K4me3). Tri-methylation at Histone
H3 lysine 9 (H3K9me3) or H3 lysine 27 (H3K27me3), however, result
in chromatin condensation and epigenetic silencing.
Histone modiﬁcations and their cell-, tissue, and signal-speciﬁc pat-
terns are complex. Together with DNAmethylation patterns they deter-
mine the phenotype and function of cells and tissues. Over the recent
years, it became clear that histone modiﬁcations contribute to the al-
tered phenotype of immune cells and the pathophysiology of SLE [2].
Globally reduced histone H3 acetylation and H3K9 methylation are re-
duced in CD4+ T cells from SLE patients [67]. Most data on SLE-related
histone modiﬁcations are available for cytokine genes (Table 3). CD4+
T cells from SLE patients exhibit permissive histone marks at the IL17
(H3K18ac ↑, H3K27me3 ↓) and the IL10 (H3K18ac ↑) gene clusters
that allow for increased gene expression (16, 35). In contrast to these
ﬁndings, the IL2 gene exhibits histone marks indicative for condensed
chromatin (H3K18ac ↓, H3K27me3 ↑) which are reﬂected by failure to
express IL-2 in T cells from SLE patients [53].
3. Molecular mechanisms orchestrating the epigenome in SLE
3.1. Regulation of DNA methylation
Over the recent years, a number of molecular mechanisms have
been identiﬁed as contributors to altered DNA methylation patterns in
SLE. Aforementioned DNMT enzymes are centrally involved in shaping
the epigenome. Several studies provided evidence of altered DNMT ex-
pression in CD4+ T cells from SLE patients. However, results were not
conclusive with both increased and reduced expression of DNMT1 and
DNMT3 in cells from SLE patients [70–72]. However, seemingly incon-
sistent results may be explained by failure to measure protein expres-
sion levels and/or protein recruitment to regulatory regions.
Furthermore, gene expression was not correlated with disease activity
in individual patients.
DNMT-directed DNA methylation is tightly controlled and depends
on signal-, target-, cell- and tissue-speciﬁc mechanisms, including pro-
tein kinase activity [36,44,45,73,74]. Reduced DNA methylation in T
cells from SLE patients has been linked with altered MAPK activity. In
patients with active disease, reduced activation of extracellular signal-
regulated kinases (ERK) or increased activity of protein phosphatases,
e.g. the serine/threonine phosphatase PP2A (that mediates ERK inacti-
vation), results in impaired activation of DNMT1 and gradual DNA de-
methylation. Reduced activation of ERK protein kinases can
furthermore be caused by impaired activity of protein kinase C δ
(PKCδ) [73,74], a hallmark of T cells from SLE patients. Indeed, altered
ERK activation and subsequent DNA demethylation through impaired
DNMT1 activity has been linked to increased expression of co-
stimulatory molecules CD11A [37,38,75], CD70 [76], CD40L [48,50],
and the pro-inﬂammatory cytokine IL-17A [36,44,45], interferon-
regulated genes [30], and the development of autoantibodies [7,24].
The DNA damage inducible protein GADD45α can mediate active
DNA demethylation through complex interactions with activation-
induced deaminase (AID), and the methyl-CpG-binding (MBD) protein
MBD4. Further involving 5-methyl-cytosine-deaminase and G:T
mismatch-speciﬁc thymine glycosylase, GADD45α can ﬁnally direct
DNA demethylation. Since GADD45α expression is increased in T cells
from patients with SLE, this mechanisms may contribute to global
DNA demethylation in SLE [7,8,77,78]. The involvement of MBD4 in ac-
tive DNA demethylation in SLE T cells was recently emphasized by Liao
et al. who suggested reducedMBD4 expression in CD4+ T cells from SLE
patients to contribute to active DNA demethylation of the CD70 pro-
moter [79]. While it currently remains unclear why aforementioned in-
creased MBD4 recruitment through GADD45α and AID, as well as
reduced MBD4 expression in SLE T cells result in DNA demethylation
at promoter regions and subsequently altered gene expression, both ob-
servations highlight a role of tightly controlledMBD4 expression and re-
cruitment in active alteration of DNA methylation in SLE..org/10.1016/j.clim.2018.02.002
Table 1
DNA methylation patterns in SLE.
Reduced DNA methylation
Gene Cell type
studied
Physiological function Proposed effects in SLE Ref.
CD6 (Cluster of
differentiation 6)
T cells T cell activation T cell activation [14]
CREM (cAMP response
element modulator) P1
promoter
T cells, CD4+ T
cells, effector
CD4+T cells
Transcription factor Generation of DN T cells; effector T cell differentiation [15–20]
ESR1 (estrogen receptor 1) PBMCs nuclear estrogen receptor Increased estrogen signaling; immune activation [21,22]
Human endogenous
retroviral elements
(HERV)
CD4+ T cells,
CD8+ T cells, B
cells
No physiological function; remainders of ancient
retroviral infections
Expression of interferon-related genes; auto-antibody
production against HERV protein products
[23–26]
IFI44L (interferon-induced
44-like protein)
PBMCs Unknown function; component of the type 1
interferon response
Immune activation [27–29]
IKZF4 (IKAROS family zinc
ﬁnger 4, encoding for
Eos)
CD4+ T cells Member of the IKAROS transcription factor family Immune activation [30]
IL4 (IL-4) CD4+ T cells Cytokine; involved in Th2 cell differentiation,
maturation, and reduced apoptosis, B cell maturation,
immunoglobulin class switch (IgE), etc.
Reduced lymphocyte apoptosis; B cell maturation;
adhesion molecule expression
[31]
IL6 (IL-6) CD4+ T cells Cytokine; B cell proliferation, immunoglobulin
production; hematopoiesis, thrombopoiesis; T cell
proliferation, differentiation, cytotoxicity; acute phase
response; etc.
B and T cell activation [32]
IL10 (IL-10) CD3+ T cells,
CD4+ T cells
Inhibition of immune cells, antigen presentation and
cytokine production
B cell activation, antibody production [33–35]
IL13 (IL-13) CD4+ T cells Closely related to IL-4 Unclear, potentially as IL-4 (see above) [33]
IL17A (IL-17A) CD3+ T cells,
CD4+ T cells,
effector CD4+T
cells
Induction of chemokines and cytokines; recruitment
of neutrophils
Induction of tissue damage [15,36]
IRF7 (Interferon regulatory
factor 7)
CD4+ T cells Activation of type I interferons Immune activation [30]
ITGAL (integrin alpha L;
CD11A)
CD4+ T cells Cellular adhesion and co-stimulation T cell activation [37–39]
KIR2DL4 (killer cell
immunoglobulin-like
receptor 2DL4; KIR)
CD4+ T cells Detection of virus-infected cells T cell activation [40–42]
MX1 (myxovirus resistance
1 gene;
interferon-induced
GTP-binding protein
Mx1)
Neutrophils GTPase, mediates resistance against RNA viruses Immune activation [28]
PP2A (serine/threonine
protein phosphatase 2A)
CD3+ T cells,
CD4+ T cells
Protein phosphatase Epigenetic remodeling of the IL17 gene cluster [36,44,45]
PRF1 (Perforin) CD4+ T cells Cytolytic protein Perforin expression in CD4+ T cells; T cell-induced
death of monocytes/macrophages
[46,47]
TNFSF5 (tumor necrosis
factor ligand superfamily
member 5;
CD40L/CD154)
CD4+ T cells B cell co-stimulation B cell co-stimulation; antibody production [42,46,48–50]
TNFSF7 (tumor necrosis
factor ligand superfamily
member 7; CD70)
CD4+ T cells B cell activation, IgG synthesis, T cell co-stimulation B cell activation, IgG synthesis; T cell co-stimulation [51]
Type I interferon response
genes IFIT1, IFIT3,MX1,
STAT1, IFI44L, USP18,
TRIM22, BST2
Naïve CD4+ T
cells
interferon-induced genes DNA hypomethylation prior to T cell
differentiation/activation suggests epigenetic poising
that allows increased reactivity to type I interferon
stimulation
[43]
Increased DNA methylation
CD8A and CD8B (Cluster of
differentiation 8A and B)
CD4+ T cells,
CD8+ T cells,
DN T cells
T cell surface co-receptor Generation of effector CD3+CD4−CD8− T cells [19,52]
IL2 (IL-2) Bulk T cells,
CD4+ T cells,
effector CD4+T
cells
Proliferation and activation of T cells Reduced numbers and altered function of regulatory T
cells; reduced activation-induced cell death; impaired
function of CD8+ T cells; effector CD4+ T cell
differentiation and cytokine expression
[8,20,53]
FOXP3
(Forkhead-Box-Protein
P3)
PBMCs Master regulator during the development and
function of Treg
Reduced numbers and altered function of regulatory T
cells
[54–56]
NOTCH1 (Notch-1
trans-membrane
receptor)
CD3+ T cells,
CD4+ T cells
T cell lineage determination T cell activation; IL-17A expression [16]
NR3C1 (nuclear receptor
subfamily 3 group C
member 1;
glucocorticoid receptor)
PBMCs Regulates development, metabolisms, immune
responses
Unknown; suspected increased immune activation [57]
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Table 2
DNA hydroxmethylation patterns in SLE.
Gene Cell
type
studied
Physiological function Proposed effects in SLE Ref.
3826 genes with disturbed
hydroxymethylation
PBMCs Unknown Immune dysregulation [66]
CDKN1A (Cyclin-dependent
kinase inhibitor 1A)
PBMCs Regulation of G1 cell cycle progression, DNA replication and DNA
damage repair; role during apoptosis
Defects in apoptosis and DNA repair
Hydroxymethylation ↑
CDKN1B (Cyclin-dependent
kinase inhibitor 1B)
PBMCs Regulation of G1 cell cycle progression Defects in apoptosis or autophagy, resulting in increased
exposure to nuclear autoantigens
Hydroxymethylation ↓
TREX1 (3′ exonuclease TREX1) PBMCs DNA repair; proof reading during DNA replication Impaired exonuclease function and cytosolic DNA
accumulation;Hydroxymethylation ↑
Association with the SET complex during granzyme A-mediated
cell death
Reduced cell death and survival of autoreactive cells
2748 genes with ↑
Hydroxymethylation
CD4+ T
cells
Unknown Immune dysregulation [64]
47 genes with ↓ DNA
hydroxymethylation
CD4+ T
cells
Unknown Immune dysregulation
SOCS1 Negative regulator of cytokine expression; role in Treg function Immune dysregulation
Hydroxymethylation ↑ CD4+ T
cells
NR2F6 (V-erbA-related protein
2 (EAR-2))
CD4+ T
cells
Nuclear orphan receptor, suppression of lymphocyte activation
and Th17 responses
Autoreactive T cell activation
Hydroxymethylation ↑
IL15RA (IL-15 receptor alpha) CD4+ T
cells
Promotion of T cell proliferation and activation Autoreactive T cell proliferation and activation
Hydroxymethylation ↑
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Currently, our knowledge about DNA hydroxymethylation, its exact
functions and underlying molecular mechanisms is very limited. Bio-
chemically, DNA hydroxymethylation is the result of methylated cyto-
sine oxidation within CpG dinucleotides by the ten eleven
translocation (TET) family of methylhydroxytransferases [80–83]. To
provide DNA hydroxymethylation, TET enzymes require co-factors, in-
cluding Fe(II) and 2-oxoglutarate [80]. TET enzymes facilitate passive
DNA demethylation and histone demethylation since
hydroxymethylated DNA fails to bind DNMT1, which is required for
DNA methylation maintenance, and methyl-CpG-binding (MBD) pro-
teins that play a role in the translation of DNA methylation patterns
into histone methylation (see below) (Fig. 1) [84]. Furthermore, activeFig. 1. The role of TET proteins during DA hydroxymethylation. A) The presence and
activity of TET proteins may be regulated by transcription of mRNA (left), altered
protein stability or translocation to the nucleus (middle), or reduced or increased
accessibility to co-factors, such as iron (Fe(II)), 2-oxoglutarate (2-oxo), or vitamin C (Vit.
C) (right). B) TET enzymes facilitate DNA hydroxymethylation in an active and passive
fashion. Active DNA demethylation can be achieved through CpG DNA oxidation. The
oxidation products are excised by DNA repair enzymes and replaced with unmethylated
cytosine. Furthermore, hydroxymethylated DNA fails to bind DNMT1 and methyl-CpG-
binding (MBD) proteins that play a role in the translation of DNA methylation patterns
into histone methylation (TF: transcription factor, RNA poly.: RNA polymerase).
Please cite this article as: C.M. Hedrich, Clin. Immunol. (2018), https://doiDNA demethylation can be achieved though TET-mediated CpG DNA
oxidation. The oxidation products 5-formylcytosine and 5-
carboxylcytosine (by not 5-hydroxymethylcytosine) are excised by
DNA repair enzymes and replaced with unmethylated cytosine [85].
3.3. Acquisition of histone modiﬁcations
A constantly growing number of enzymes have been reported to
mediate speciﬁc epigenetic changes that allow ﬁne-tuning of gene ex-
pression patterns. Posttranslational modiﬁers of N-terminal amino
acid residues of histone proteins include lysine-speciﬁc histone acetyl-
transferases (HATs), histone deacetylases (HDACs), lysine-speciﬁc
methyltransferases (KMTs), and lysine demethylases (KDMs) [2,86].
Histone modiﬁcations cannot be understood and are not regulated
as isolated events. They are mechanistically and functionally linked
with DNA methylation and hydroxymethylation patterns. The family
of methyl-CpG-binding (MBD) proteins play a role in the solidiﬁcation
of DNA methylation mediated transcriptional repression through the
recruitment of additional epigenetic modiﬁers. Six MBD family mem-
bers include MBD1 throughMBD4, Kaiso, andmethyl-CpG binding pro-
tein 2 (MeCP2), structural proteins that recruit histone deacetylases
(HDACs) and others to genomic regions with high DNA methylation
[2,87,88]. This contributes to the translation of DNA methylation pat-
terns into silencing histone modiﬁcations. Thus, aforementioned re-
duced MBD4 expression in T cells from SLE patients likely not only
mediate gradual DNA demethylation of the CD70 promoter, but also
contribute to reduced solidiﬁcation of DNA methylation patterns
though the translation into histone modiﬁcations potentially across
the genome [79].
3.4. Transcription factors orchestrate multi-dimensional epigenetic remod-
eling in SLE
The transcription regulatory factor cAMP response elementmodula-
tor α (CREMα) is expressed at increased levels in T cells from patients
with SLE. It centrally contributes to T cell dysfunction and resulting tis-
sue damage [89,90]. CREMα belongs to the CREM superfamily of tran-
scription factors that comprises more than 50 known isoforms [91].
Hormones and growth factors induce cAMP generation through.org/10.1016/j.clim.2018.02.002
Table 3
Histone modiﬁcations in SLE.
Gene Modiﬁcation Cell type
studied
Physiological function Proposed effects in SLE Ref.
CD8A, CD8B
(Cluster of
differentiation
8A and 8B)
H3K18ac ↓,
H3K27me3 ↑
during DN T cell
generation
CD4+ T cells,
CD8+ T cells,
DN T cells
Lineage-deﬁning surface co-receptor Generation of CD3+CD4−CD8− DN T cells [19,52]
ITGAL (integrin
alpha L gene;
CD11A)
H3K27me3 ↓ CD4+ T cells Cellular adhesion and co-stimulation T cell-mediated inﬂammation [68]
IL2 (IL-2) H3K18ac ↓,
H3K27me3 ↑
CD3+ T cells,
CD4+ T cells,
effector
CD4+T cells
Proliferation and activation of T cells Regulatory T cells ↓; activation-induced cell death ↓ and
longer survival of autoreactive T cells; function of
cytotoxic CD8+ T cells ↓; effector CD4+ T cell
differentiation and cytokine expression ↑
[20,53]
IL10 (IL-10) H3K18ac ↑ CD3+ T cells,
CD4+ T cells
Inhibition of T cell activation, B cell differentiation,
activation, and immunoglobulin production
B cell activation, (auto-) antibody production [35]
IL17A (IL-17A) H3K18ac ↑ CD3+ T cells,
CD4+ T cells,
effector
CD4+T cells
Induction of chemokines and cytokines; recruitment
of neutrophils
Tissue damage in SLE [15,36]
TNF (Tumor
necrosis factor
alpha)
H3ac ↑ Monocytes Monocyte activation, cytokine and prostaglandin
production, priming of mononuclear cells, apoptosis,
oxidative burst, induction of endothelial cell adhesion
molecules and cytokine release, T cell apoptosis, etc.
Increased monocyte maturation and pro-inﬂammatory
cytokine expression
[69]
5C.M. Hedrich / Clinical Immunology xxx (2018) xxx–xxxadenylate cyclase, which in turn promotes the activation of protein ki-
nases that activate CREM. Alternatively, T cell receptor complex (TCR)
activation and calcium inﬂux activate protein kinases, subsequently
resulting in the activation of CREM family transcription factors [92,93].
In T cells, CREMα acts as transcriptional regulator with complex func-
tion. While it represses some genes, CREMα activates others. In CD4+
T cells from SLE patients, CREMα contributes to the imbalanced expres-
sion of IL-2 and IL-17A [2,15,16,20,53,91,94–96]. It recruits to the IL2
proximal promoter and mediates trans-repression and epigenetic re-
modeling through interactions with histone deacetylase HDAC1 and
DNA methyltransferase DNMT3a [20,53,96] which mediate histone
de-acetylation and DNAmethylation. At the same time, CREMα orches-
trates epigenetic ‘opening’ of the IL17 gene cluster, comprising the pro-
inﬂammatory homologues IL17A and IL17F [15,20]. CREMα recruits to
the IL17A and IL17F proximal promoters in T cells from SLE patients
[15,16]. Here, CREMα fails to recruit DNMT3a and HDAC1while it actu-
ally induces DNA de-methylation and histone acetylation [15,16,20].Fig. 2. CREMα instructs epigenetic ‘opening’ of the IL17 cluster. A) The transcription factor C
mechanisms are currently unclear, CREMα instructs DNA demethylation (black open circles)
acetyltransferase p300 and co-localization with the transcription factor Stat3 may be involv
interactions between CREMα and p300. T cells from healthy controls (Contr.) and SLE patie
plate-bound anti-CD3 and anti-CD28 antibodies (ST). Nuclei are DAPI stained (blue), gree
references to colour in this ﬁgure legend, the reader is referred to the web version of this artic
Please cite this article as: C.M. Hedrich, Clin. Immunol. (2018), https://doiThe exact mechanisms are currently unknown. However, this observa-
tion is in agreement with observations in male germ cells, where the
CREM isoform CREMτmediates histone acetylation [97]. The observa-
tion that CREMα interacts with the histone acetyltransferase p300 is
of special interest in this context [96]. While CREMα recruits p300 to
the IL2 promoter, where p300 fails to be activated, the different tran-
scription factor micro-environment at the IL17 cluster may allow for
p300 activation and histone acetylation [96,98]. Since p300 can physi-
cally and functionally link transcription factors, and since interactions
with signal transducer and activator of transcription (Stat) family tran-
scription factors mediate histone acetylation through p300 [35], a func-
tional interaction between CREMα and Stat3 at IL17A appears likely
(Fig. 2). Indeed, at the IL10 gene, Stat 3 recruits to regulatory elements
in the proximal promoter and the 4th intron where it co-recruits p300
resulting in histone acetylation and epigenetic ‘opening’ [35].
CD3+TCR+CD4−CD8− “double negative” (DN) T cells exhibit effec-
tor phenotypes and are increased in number in the peripheral blood ofREMα recruits to regulatory elements along the IL17 cluster. While the exact molecular
and histone H3K18ac (blue circles). It appears likely that co-recruitment of the histone
ed. B) Representative images from proximity ligation assays (PLAs) indicating physical
nts were investigated under resting conditions (NS) or in response to stimulation with
n signals indicate interactions between CREMα and p300. (For interpretation of the
le.)
.org/10.1016/j.clim.2018.02.002
Fig. 4. The CREM promoter P1 is regulated by chromatin remodeling. Expression of the
transcription factor CREMα is under the control of the CREM promoter P1. A) DNA
methylation and inactivating histone marks silence CREMα expression. B) In effector T
cells from SLE patients, DNA demethylation (black open circles) and Set1-mediated
H3K4 tri-methylation (yellow circles) allow gene expression. CREMα expression is
controlled by the transcription factor AP-1, which can co-recruit Set1 to regulatory
regions. Though not experimentally proven for the CREM promoter P1, AP-1-directed
recruitment of Set1 may contribute to increased CREMα expression in T cells from SLE
patients. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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where they produce IL-17A and contribute to tissue damage [99,100].
We recently demonstrated that DN T cells can derive from CD8+ T
cells through the down-regulation of surface CD8 co-receptor expres-
sion (6, 18, 100). CREMα plays a central role in this process, since it re-
cruits to conserved elements within the CD8 cluster. Indeed, CREMα
trans-represses the CD8B promoter and co-recruits DNMT3a and his-
tonemethyltransferase G9a to regulatory elementswithin the CD8 clus-
ter instructing epigenetic silencing and down-regulation of CD8A and
CD8B expression (6, 18) (Fig. 3).
Of note, CREMα is not only directing epigenetic remodeling in effec-
tor T cells, it is also regulated on the epigenetic level. The CREM pro-
moter P1 is responsible for the trans-regulation of CREMα. P1 is
regulated by trans-activation through the transcription factor activating
protein 1 (AP-1), which consists of the subunits c-Jun and c-Fos [101].
Transcription factor recruitment to P1 is regulated by DNAmethylation
and histone H3K4me3 [15–20,102] (Fig. 4A). In T cells from patients
with SLE, reduced DNA methylation and increased H3K4me3 mediates
epigenetic ‘opening’ of the promoter region and increased CREM tran-
scription. Indeed, P1 H3K4me3, DNA methylation and CREMα mRNA
expression reﬂect disease activity. While reduced DNA methylation
and increased H3K4me3 allow transcription factor binding, including
AP-1, Zhang et al. demonstrated that histone methyltransferase Set1 is
responsible for the induction of H3K4me3 at P1. Since AP-1 co-recruits
Set1 to other genes, it appears likely that this mechanisms may also be
involved in the induction of epigenetic remodeling of CREM P1, since
AP-1 recruitment to P1 is increased in SLE patients [101,103] (Fig. 4B).
3.5. Demographic and environmental factors affect the epigenome
Female gender is a strong contributor to the pathophysiology of SLE,
andwomen are 9–10 timesmore frequently affectedwhen compared to
men. Estrogens affect T cell differentiation and subset distribution by
the induction of epigenetic remodeling [104–107]. Indeed, estrogen re-
ceptor signaling enhances the expression of the transcriptional regula-
tor CREMα, which exerts aforementioned strong effects on the
epigenome in T cells favouring effector phenotypes [21,91].
In addition to estrogen levels, the presence of a second X chromo-
some in women contributes to increased SLE prevalence in women. A
complex epigenetic event, referred to as X chromosome inactivation in-
volves DNA methylation, histone modiﬁcations and non-coding RNA
expression, and controls X chromosomal gene expression in women
[2]. A number of X chromosomal genes contribute to the pathophysiol-
ogy of SLE and other autoimmune disorders in a dose-speciﬁc manner
[108]. Epigenetic disturbances at X chromosomal TNFSF5 (CD40L) result
in increased expression and immune dysregulation [50] (Table 1).
The “typical” gender distribution of adult-onset SLE is not present in
the elderly. Indeed, elderly men exhibit even greater SLE incidences
when compared to elderly women. With increasing age, epigenetic al-
terations accumulate and affect gene expression patterns [46]. A possi-
ble explanation may be reduced expression and activity of DNMT1
[51]. Subsequent gradual demethylation of genomic DNA may resultFig. 3. CREMα instructs epigenetic “closing” of the CD8 cluster. The transcription factor
CREMα recruits to regulatory elements along the CD8 cluster. At CD8A and CD8B,
CREMα co-recruits the DNA methyltransferase DNMT3a and histone methyltransferase
G9a instructing DNA methylation (black ﬁlled circles) and H3K27 tri-methylation
(orange circles), resulting in DNA condensation and epigenetic silencing.
Please cite this article as: C.M. Hedrich, Clin. Immunol. (2018), https://doiin the accumulation of so-called senescent T cells that are characterized
by reduced expression of the surface co-receptor CD28, reduced telo-
mere length, and increased expression of lupus-associated “inﬂamma-
tory genes” [31,41,109].
Several environmental and chemical exposures can induce epige-
netic remodeling and contribute to autoimmune phenomena. Hydral-
azine, a therapeutic agent used to treat hypertension, inhibits the
protein kinase PKCδ. As mentioned above, reduced activity of PKCδ re-
sults in impaired ERK activation and altered activity of DNMT1 [73,74].
Methionine adenosyl transferase (MAT) is a redox-sensitive enzyme
in the S-adenosyl methionine (SAM) cycle. In the presence of adenosine
triphosphate (ATP),MAT convertsmethionine into SAM [110]. Thus, the
availability of methionine may directly affect SAM generation. Since
global DNAmethylation is reduced in the elderly andmay in some indi-
viduals contribute to autoimmune phenomena, alterations in the SAM
cycle, and/or reduced dietary intake of methionine together with re-
duced DNMT1 activity may be central mechanisms [111].
As mentioned above, increased activity of GADD45α can result in
gradual DNA demethylation in SLE patients. This is also of interest in
the context of environmental exposure, since GADD45α is induced by
UV irradiation, which is also a known trigger of disease ﬂares in SLE
and other autoimmune disorders [59,78,112].
4. Epigenetic events as therapeutic targets
As mentioned above, epigenetic alterations in autoimmune disease
can be caused or affected by behaviour and environmental exposure.
Thus, reduction of exposure to certain chemicals, UV light, etc. is already
included in recommendation for patients.
In contrast to cancer therapy, “epigenetic treatment” is not currently
available for SLE. However, several already available treatment options
affect the epigenome andmay correct alterations in SLE patients. Meth-
otrexate, which is used in SLE patients with arthritis or skin involve-
ment, can reduce the activity of DNMT1 by depleting SAM [113,114]
and thereby affect regionally increased DNA methylation (e.g. CD8,
IL2). Mitochondria are involved in oxidative stress. Activation of the en-
zyme mechanistic target of rapamycin (mTOR), they regulate DNA
methylation through the inhibition of DNMT1 [73]. Antioxidants are al-
ready available, and indeed can reduce oxidative stress andmTOR activ-
ity, as shown forN-acetylcysteine [115–117]. Cyclophosphamide is used
in individuals with severe SLE. It increases DNAmethylation through in-
duction of DNMT1 activity [51] and may therefore correct the expres-
sion of genes with reduce DNA methylation (e.g. IL17, IL10, etc.)..org/10.1016/j.clim.2018.02.002
7C.M. Hedrich / Clinical Immunology xxx (2018) xxx–xxxHowever, all of these effects are not targeted and can cause severe side-
effects.
To date, no targeted approaches are available to correct DNA
hydroxymethylation patterns. However, data indicates reduction of
DNA hydroxymethylation in RA patients in response to methotrexate
treatment [59,118]. Studies in cancer promise potential for indirect
TET inhibition. The IDH1 inhibitors AGI-5198 and HMS-101 reduce
DNA hydroxymethylation in tumor cell lines, whichmay be translatable
to autoimmune/inﬂammatory disease [119,120].
Histone modiﬁcations have not directly been targeted in SLE treat-
ment yet. However, several available treatment alter the histone code.
Mycophenolate mofetil inﬂuences histone marks while not changing
DNA methylation [121]. Inhibitors of the histone methyltransferase
G9a (e.g. tramezostat) are in the pre-clinical phase of cancer studies
[122]. Several available drugs act as inhibitors of HDAcs, including
suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA),
which both ameliorate disease in lupus-pronemice [123,124]. However,
treatment with valproic acid (that also inhibits HDACs) can cause SLE-
like disease in patients with epilepsy [125].
Taken together, preliminary observations indicate effects of already
available treatment options and “new” treatments on chromatin confor-
mation and gene expression. However, effects are not targeted and lack
region or gene speciﬁcity. Thus, beneﬁcial effects at one or several genes
may coincide with dysregulation of previously unaffected genes.
Targeted approaches aiming at underlying molecular alterations (e.g.
transcription factor expression, etc.) may allow individualized correc-
tion of epigenetic alterations in the future.
5. Conclusions
The identiﬁcation of epigenetic alterations as contributors to SLE has
improved our understanding of disease pathology. Linking epigenetic
patterns with contributing molecular events has further improved our
understanding and delivered explanations for (at least some) demo-
graphic and environmental contributors. These advances promise po-
tential for future applications in disease prevention and/or
individually tailored and target-directed therapeutic approaches. How-
ever, additional studies are needed to ﬁll in the blanks and allow the ap-
plication of epigenetic patterns as disease biomarkers and/or
therapeutic targets. To achieve this, cautiously planned collaborative
approaches are necessary to link prospectively collected and meaning-
ful clinical datasets with associated genetic and epigenetic patterns, un-
derlying molecular contributors, and disease outcomes.
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